Literature DB >> 31297863

Inhibition of miR-181b-5p protects cardiomyocytes against ischemia/reperfusion injury by targeting AKT3 and PI3KR3.

Limei Yuan1, Lihua Fan2, Qinghai Li2, Wei Cui2, Xuechen Wang2, Zhiguo Zhang2.   

Abstract

Ischemic heart disease (IHD) is the most occurring cardiovascular-associated disease, which is a primary leading cause of cardiac disability and death worldwide. Myocardial ischemia/reperfusion injury (MI/RI) has been linked to IHD-induced cardiomyocytes apoptosis and tissue damage. The clinical studies have indicated that pathophysiologic mechanisms of MI/RI are associated with reactive oxygen species generation, calcium overload, energy metabolism disorder, neutrophil infiltration, and others. However, the genetic mechanism of MI/RI remains unclear. In this study, we successfully established the reproducing abnormal heart observed in rat, of IHD-induced MI/RI post operation. By using these rats, we illustrated that expression of miR-181b-5p was increased not only in both hypoxia/reoxygenation-cultured H9C2 but also heart of myocardial ischemia/reperfusion (MI/R) rat. Suppression of the miR-181b-5p cardiomyocytes apoptosis and rescued myocardial infarction. Additionally, our data indicated that miR-181b-5p negatively regulates the expression of AKT3 and PIK3R3 through directly binding with its 3'-untranslated region. More importantly, suppression of miR-181b-5p protects the cardiomyocytes apoptosis and tissue damage from MI/R via regulation of PIK3R3 and AKT3. Hence, our study indicates that miR-181b-5p is essential for MI/RI via regulation of PI3K/Akt signaling pathway and could be a potential therapeutic target in IHD.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  PI3K/Akt signaling; apoptosis; ischemic heart disease; miR-181; myocardial ischemia/reperfusion injury

Year:  2019        PMID: 31297863     DOI: 10.1002/jcb.29271

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  MicroRNA-503 Exacerbates Myocardial Ischemia/Reperfusion Injury via Inhibiting PI3K/Akt- and STAT3-Dependent Prosurvival Signaling Pathways.

Authors:  Yanjing He; Yin Cai; Tianhao Sun; Liangqing Zhang; Michael G Irwin; Aimin Xu; Zhengyuan Xia
Journal:  Oxid Med Cell Longev       Date:  2022-05-17       Impact factor: 7.310

2.  Rno-microRNA-30c-5p promotes myocardial ischemia reperfusion injury in rats through activating NF-κB pathway and targeting SIRT1.

Authors:  Jianfeng Chen; Mingming Zhang; Shouyan Zhang; Junlong Wu; Shufeng Xue
Journal:  BMC Cardiovasc Disord       Date:  2020-05-20       Impact factor: 2.298

3.  Circ_0045714/miR-331-3p interaction affects IL-1β-evoked human articular chondrocyte injury through regulating PIK3R3 in a ceRNA regulatory cascade.

Authors:  Ran Ding; Jinsong Zhou; Jianguo Xu; Huajie Lu; Tingting Zhang; Xiong Xiang; Zhen Shi
Journal:  J Orthop Surg Res       Date:  2021-10-14       Impact factor: 2.359

4.  Inhibition of TGFβ-activated protein kinase 1 ameliorates myocardial ischaemia/reperfusion injury via endoplasmic reticulum stress suppression.

Authors:  Jingjing Zeng; Qike Jin; Yongxue Ruan; Changzheng Sun; Guangyu Xu; Maoping Chu; Kangting Ji; Lianpin Wu; Lei Li
Journal:  J Cell Mol Med       Date:  2020-05-07       Impact factor: 5.310

5.  Neuroprotective effect of 3,3'-Diindolylmethane against perinatal asphyxia involves inhibition of the AhR and NMDA signaling and hypermethylation of specific genes.

Authors:  J Rzemieniec; E Bratek; A Wnuk; K Przepiórska; E Salińska; M Kajta
Journal:  Apoptosis       Date:  2020-08-20       Impact factor: 4.677

6.  Nobiletin alleviates ischemia/reperfusion injury in the kidney by activating PI3K/AKT pathway.

Authors:  Bo Liu; Quanhong Deng; Lei Zhang; Wen Zhu
Journal:  Mol Med Rep       Date:  2020-10-01       Impact factor: 2.952

Review 7.  The Regulation Mechanisms and Clinical Application of MicroRNAs in Myocardial Infarction: A Review of the Recent 5 Years.

Authors:  Chan Wu; Binghong Liu; Ruiying Wang; Gang Li
Journal:  Front Cardiovasc Med       Date:  2022-01-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.